Cognitive Trajectories in Community-Dwelling Older Adults and Incident Dementia, Disability and Death: A 10-Year Longitudinal Study.

Autor:	Wu Z; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Woods RL; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Chong TTJ; Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.; Department of Neurology, Alfred Health, Melbourne, VIC, Australia.; Department of Clinical Neurosciences, St Vincent's Hospital, Melbourne, VIC, Australia., Orchard SG; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Shah RC; Department of Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, United States., Wolfe R; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Storey E; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Sheets KM; Division of Geriatrics and Palliative Medicine, Department of Medicine, Hennepin Healthcare, Minneapolis, MN, United States., Murray AM; Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Minneapolis, MN, United States., McNeil JJ; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia., Ryan J; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2022 Jun 27; Vol. 9, pp. 917254. Date of Electronic Publication: 2022 Jun 27 (Print Publication: 2022).
DOI:	10.3389/fmed.2022.917254
Abstrakt:	Objective: The inter-individual variability in cognitive changes may be early indicators of major health events. We aimed to determine whether late-life cognitive trajectories were associated with incident dementia, persistent physical disability and all-cause mortality. Methods: Data came from a cohort of older community-dwelling individuals aged 70 years or above in Australia and the United States. Global cognition, verbal fluency, episodic memory and psychomotor speed were assessed regularly at up to seven waves between 2010 and 2017. Dementia, disability in activities of daily living, and death were adjudicated between 2017 and 2020. Latent classes of cognitive trajectories over seven years were determined using group-based trajectory modeling. Multivariable logistic regression was used for the prospective associations between cognitive trajectories and these outcomes. Results: Cognitive trajectories were defined for 16,174 participants (mean age: 78.9 years; 56.7% female) who were alive and without incident dementia or disability by 2017, among which 14,655 participants were included in the association analysis. Between three and five trajectory classes were identified depending on the cognitive test. Cognitive trajectories were strongly associated with the risk of dementia. For example, compared to those in the highest-functioning trajectory, the worst performers of episodic memory had a 37-fold increased risk of dementia (95% CI: 17.23-82.64). The lowest trajectories of both global cognition and episodic memory also predicted increased mortality risk (OR: 1.80, 95% CI: 1.28-2.52; OR: 1.61, 95% CI: 1.09-2.36, respectively), while only slow psychomotor speed was marginally associated with physical disability (OR: 2.39, 95% CI: 0.99-5.77). Conclusions: In older individuals, cognitive trajectories appear to be early indicators of clinically relevant health outcomes. Systematic cognitive assessments as part of routine geriatric evaluation may facilitate early identification and interventions for those individuals at highest risk. Competing Interests: AM reports receiving consulting fees from Alkahest, Inc. and grants from the National Institute on Aging. RS reports grants for clinical research regarding dementia and Alzheimer's disease from the National Institutes of Health, the Centers for Medicare and Medicaid Services, the Department of Defense, and the Illinois Department of Public Health; being as a non-compensated member of the Board of Directors of the Alzheimer's Association–Illinois Chapter; and being as a site principal investigator or sub-investigator for clinical trials and research studies for which his institution (Rush University Medical Center) is sponsored (Amylyx Pharmaceuticals, Inc., Eli Lilly & Co., Inc., Genentech, Inc., Lundbeck, Inc., Merck & Co, Inc., Navidea Biopharmaceuticals, Novartis Pharmaceuticals, Inc., Roche Holdings AG, and Takeda Development Center Americas, Inc.). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Wu, Woods, Chong, Orchard, Shah, Wolfe, Storey, Sheets, Murray, McNeil and Ryan.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu